India, Sept. 4 -- Cohance Lifesciences today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%.Dr. Jain will continue to lead NJ Bio while also advancing Aruka's pipeline and partnership initiatives.NJ Bio will remain focused on customer-facing contract research, development and manufacturing services. Closer integration will combi...